Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA064514-07
Application #
6128304
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Crowell, James A
Project Start
1995-04-01
Project End
2001-02-28
Budget Start
2000-08-01
Budget End
2001-02-28
Support Year
7
Fiscal Year
2000
Total Cost
$154,489
Indirect Cost
Name
Amc Cancer Research Center
Department
Type
DUNS #
City
Denver
State
CO
Country
United States
Zip Code
80214
Singh, Rana P; Agarwal, Rajesh (2009) Cosmeceuticals and silibinin. Clin Dermatol 27:479-84
Ramasamy, Kumaraguruparan; Agarwal, Rajesh (2008) Multitargeted therapy of cancer by silymarin. Cancer Lett 269:352-62
Deep, Gagan; Agarwal, Rajesh (2008) New combination therapies with cell-cycle agents. Curr Opin Investig Drugs 9:591-604
Raina, Komal; Agarwal, Rajesh (2007) Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin 28:1466-75
Kaur, Manjinder; Agarwal, Rajesh (2007) Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol 224:350-9
Gu, Mallikarjuna; Singh, Rana P; Dhanalakshmi, Sivanandhan et al. (2007) Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res 67:3483-91
Singh, Rana Pratap; Agarwal, Rajesh (2006) Natural flavonoids targeting deregulated cell cycle progression in cancer cells. Curr Drug Targets 7:345-54
Singh, Rana P; Agarwal, Rajesh (2004) Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 4:1-11
Mohan, Sarumathi; Dhanalakshmi, Sivanandhan; Mallikarjuna, G U et al. (2004) Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 320:183-9
Singh, Rana P; Agarwal, Rajesh (2003) Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr Cancer Drug Targets 3:205-17